Literature DB >> 12693805

Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community.

C von Plessen1, O Grinde, A Gulsvik.   

Abstract

This study assesses the incidence and prevalence of cryptogenic fibrosing alveolitis (CFA) in a well-defined and stable Norwegian population of 250,000 inhabitants during a period of 15 years. We conducted a file survey of all patients (n = 376) aged 16 years or older with a clinician's diagnosis of pulmonary fibrosis (ICD 8: 517 and ICD 9: 515 and 516). Cases with a history of exposure to fibrogenic agents or with collagen vascular disease were excluded and the remaining 158 cases were defined as CFA. The average annual incidence of hospitalised CFA was 4.3 per 100,000. No change was observed in the annual incidence during the 15-year study period. The prevalence was 19.7 and 23.9 per 100,000 by 31.12. 1991 and by 31.12. 1998, respectively. The incidence increased considerably and significantly with age. No significant gender differences were observed. The lack of gender differences and the increase with age were also found when the diagnosis of CFA was exclusively based on cases with hospital file records of breathlessness, bilateral crackles and bilateral shadows on chest radiograph.

Entities:  

Mesh:

Year:  2003        PMID: 12693805     DOI: 10.1053/rmed.2002.1466

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  15 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 2.  Idiopathic pulmonary fibrosis: The current status of its epidemiology, diagnosis, and treatment in China.

Authors:  Haibo Huang; Xiaonu Peng; Chongwen Zhong
Journal:  Intractable Rare Dis Res       Date:  2013-08

3.  Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.

Authors:  Evans R Fernández Pérez; Craig E Daniels; Darrell R Schroeder; Jennifer St Sauver; Thomas E Hartman; Brian J Bartholmai; Eunhee S Yi; Jay H Ryu
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

Review 4.  Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.

Authors:  Ulrich Costabel; Elisabeth Bendstrup; Vincent Cottin; Pieter Dewint; Jim J J Egan; James Ferguson; Richard Groves; Per M Hellström; Michael Kreuter; Toby M Maher; Maria Molina-Molina; Klas Nordlind; Alexandre Sarafidis; Carlo Vancheri
Journal:  Adv Ther       Date:  2014-03-18       Impact factor: 3.845

5.  Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry.

Authors:  Juergen Behr; Marius M Hoeper; Michael Kreuter; Jens Klotsche; Hubert Wirtz; David Pittrow
Journal:  BMJ Open Respir Res       Date:  2014-01-03

Review 6.  IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe.

Authors:  Annette Duck; Lucy Pigram; Peter Errhalt; Deeba Ahmed; Nazia Chaudhuri
Journal:  Adv Ther       Date:  2015-02-18       Impact factor: 3.845

7.  Retrospective observational study of trends in hospital admissions for idiopathic pulmonary fibrosis in Spain (2004-2013) using administrative data.

Authors:  Fernando Pedraza-Serrano; Ana López de Andrés; Rodrigo Jiménez-García; Isabel Jiménez-Trujillo; Valentín Hernández-Barrera; Gema Sánchez-Muñoz; Luis Puente-Maestu; Javier de Miguel-Díez
Journal:  BMJ Open       Date:  2017-02-13       Impact factor: 2.692

8.  Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review.

Authors:  Sabrina Carvajalino; Carla Reigada; Miriam J Johnson; Mendwas Dzingina; Sabrina Bajwah
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

Review 9.  Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data.

Authors:  Jaana Kaunisto; Eija-Riitta Salomaa; Ulla Hodgson; Riitta Kaarteenaho; Marjukka Myllärniemi
Journal:  BMC Pulm Med       Date:  2013-08-20       Impact factor: 3.317

Review 10.  Epidemiology of idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard
Journal:  Clin Epidemiol       Date:  2013-11-25       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.